Business Process Management
MBIB-BPM-14
Assignment Cover Page
Student Number Student Name Signature
1701442 Saskia Hoekstra
1699287 Anne Lueb
Class: L2C
Teacher: Helen Xu
Date of Publication: 3 November 2017
, Index
Introduction .......................................................................................................................... 3
Analysis AS-IS situation.......................................................................................................... 4
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) .................................. 4
Purchasing and shipment of excipients ................................................................................... 4
Purchasing of drugs products, blisters and leaflets .................................................................. 4
Production of the drug product ................................................................................................ 4
Packaging................................................................................................................................. 5
Quality control ......................................................................................................................... 5
Quality assurance ..................................................................................................................... 5
Where does waste occur? ...............................................................................................................5
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) .................................. 5
Purchasing and shipment of excipients ................................................................................... 6
Purchasing of drugs products, blisters and leaflets .................................................................. 6
Production of the drug product ................................................................................................ 6
Packaging................................................................................................................................. 7
Quality control ......................................................................................................................... 7
Quality assurance ..................................................................................................................... 7
Overall ..................................................................................................................................... 8
Current lead time As-Is ...................................................................................................................9
Possible improvements of the AS-IS-situation ...................................................................... 10
To-be process BIZZdesign ............................................................................................................. 10
Recommendations ....................................................................................................................... 10
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) ................................ 10
Purchasing and shipment of excipients ......................................................................................... 11
Purchasing of drug product, blisters, and leaflets .......................................................................... 11
Production of the drug product .............................................................................................. 12
Packaging............................................................................................................................... 12
Quality control ....................................................................................................................... 13
Quality assurance ................................................................................................................... 13
Estimated results in lead-time ...................................................................................................... 14
Financial estimate of effects ................................................................................................ 15
AS-IS ..................................................................................................................................... 15
TO-BE ................................................................................................................................... 16
Conclusion........................................................................................................................... 18
Bibliography ........................................................................................................................ 19
Appendices ......................................................................................................................... 20
Appendix 1, AS-IS and TO-BE process ............................................................................................ 20
Appendix 2, Task division ............................................................................................................. 22
2
, Introduction
BAYER AG is a German global enterprise, focusing on the fields regarding to life science of health
care and agriculture. One of their primary areas of business include veterinary and human
pharmaceuticals, and consumer healthcare. This report will be focused on the last .
Although BAYER AG operates all over the world, employees around the 115.000 employees (AG,
2017) and has most of its customers located in Western Europe, and the United States. There
was still a degrease in profit. One of the main reasons is competition, and the tender system.
BAYER AG has to act before these loses in profit will rise even higher. Therefore, we will analyze
the current As-Is situation of BAYER AG, eliminate the wastes and bottlenecks that occur, in order
to come up with a good proposal for BAYER AG. Costs, lead-time,
and overall improvement will be taken into consideration. We aim
to reduce the current maximal lead-time of 280 by at least 50%
and total costs by 10%.
Since BAYER AG is currently facing major penalties (1 million
euros), because they fail to supply 50% of the tender within 60
business days.
To provide BAYER AG with a proposal of high quality, our agency:
‘GetBetter’ will work on this as a team and study the case
together. We will use the concepts of Slack as a starting point.
3
MBIB-BPM-14
Assignment Cover Page
Student Number Student Name Signature
1701442 Saskia Hoekstra
1699287 Anne Lueb
Class: L2C
Teacher: Helen Xu
Date of Publication: 3 November 2017
, Index
Introduction .......................................................................................................................... 3
Analysis AS-IS situation.......................................................................................................... 4
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) .................................. 4
Purchasing and shipment of excipients ................................................................................... 4
Purchasing of drugs products, blisters and leaflets .................................................................. 4
Production of the drug product ................................................................................................ 4
Packaging................................................................................................................................. 5
Quality control ......................................................................................................................... 5
Quality assurance ..................................................................................................................... 5
Where does waste occur? ...............................................................................................................5
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) .................................. 5
Purchasing and shipment of excipients ................................................................................... 6
Purchasing of drugs products, blisters and leaflets .................................................................. 6
Production of the drug product ................................................................................................ 6
Packaging................................................................................................................................. 7
Quality control ......................................................................................................................... 7
Quality assurance ..................................................................................................................... 7
Overall ..................................................................................................................................... 8
Current lead time As-Is ...................................................................................................................9
Possible improvements of the AS-IS-situation ...................................................................... 10
To-be process BIZZdesign ............................................................................................................. 10
Recommendations ....................................................................................................................... 10
Outsourcing and shipment of Active Pharmaceutical Ingredient (API) ................................ 10
Purchasing and shipment of excipients ......................................................................................... 11
Purchasing of drug product, blisters, and leaflets .......................................................................... 11
Production of the drug product .............................................................................................. 12
Packaging............................................................................................................................... 12
Quality control ....................................................................................................................... 13
Quality assurance ................................................................................................................... 13
Estimated results in lead-time ...................................................................................................... 14
Financial estimate of effects ................................................................................................ 15
AS-IS ..................................................................................................................................... 15
TO-BE ................................................................................................................................... 16
Conclusion........................................................................................................................... 18
Bibliography ........................................................................................................................ 19
Appendices ......................................................................................................................... 20
Appendix 1, AS-IS and TO-BE process ............................................................................................ 20
Appendix 2, Task division ............................................................................................................. 22
2
, Introduction
BAYER AG is a German global enterprise, focusing on the fields regarding to life science of health
care and agriculture. One of their primary areas of business include veterinary and human
pharmaceuticals, and consumer healthcare. This report will be focused on the last .
Although BAYER AG operates all over the world, employees around the 115.000 employees (AG,
2017) and has most of its customers located in Western Europe, and the United States. There
was still a degrease in profit. One of the main reasons is competition, and the tender system.
BAYER AG has to act before these loses in profit will rise even higher. Therefore, we will analyze
the current As-Is situation of BAYER AG, eliminate the wastes and bottlenecks that occur, in order
to come up with a good proposal for BAYER AG. Costs, lead-time,
and overall improvement will be taken into consideration. We aim
to reduce the current maximal lead-time of 280 by at least 50%
and total costs by 10%.
Since BAYER AG is currently facing major penalties (1 million
euros), because they fail to supply 50% of the tender within 60
business days.
To provide BAYER AG with a proposal of high quality, our agency:
‘GetBetter’ will work on this as a team and study the case
together. We will use the concepts of Slack as a starting point.
3
